ClinicalTrials.gg
RecruitingNCT06813352FibromyalgiaUpdated Nov 19, 2025

Analysis of Facial Expressions for Pain Recognition in Fibromyalgia: Using Artificial Intelligence and Biomarkers

An observational study in Fibromyalgia (FM), Pain and Catastrophizing Pain, sponsored by Faculdade de Ciências Médicas de Minas Gerais. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Faculdade de Ciências Médicas de Minas Gerais · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
122
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Fibromyalgia with a site in Brazil — 6 open to participants now, 8 under way, none of them phase 3. Fibromyalgia · Brazil.

Started
2025
with 4 others
Observational
2 of 60
1 open now
Registered
55th of 60
by date

Among the 60 studies in Fibromyalgia with a site in Brazil, this one is one of 5 that started in 2025, is one of 2 observational ones, and was the 55th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

6 of the 60 studies in Fibromyalgia with a site in Brazil are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Fibromyalgia with a site in Brazil, or all of them as a file.
02

Study summary

Fibromyalgia (FM) is a chronic musculoskeletal pain syndrome with characteristics of generalized body pain, low pain threshold, tenderness and stiffness in muscles, tendons and joints. The assessment of pain in this condition is a challenge due to its subjective nature. A promising approach to assessing pain intensity is facial expression analysis, which can serve as an objective indicator. In addition, research seeks to identify molecular molecular markers to quantify pain. However, the lack of a standardized system has made it difficult to identify reliable markers. In summary, the search for objective methods of assessing pain in fibromyalgia is essential in order to develop more effective more effective treatments. Facial expression analysis and the investigation of molecular markers are promising ways of quantifying pain intensity more accurately and intensity of pain more accurately and reliably in fibromyalgia.

Read the detailed description

Introduction:

Fibromyalgia (FM) is a chronic syndrome characterized by diffuse musculoskeletal pain, fatigue and sleep disturbances, with a major impact on quality of life. Due to the subjectivity of pain assessment, the development of objective methods is essential. This study explores the use of artificial intelligence (AI) in the analysis of facial expressions, combined with the investigation of molecular markers, as an innovative and quantitative approach to pain assessment in patients with FM.

Objective:

To validate the application of an AI tool combined with facial expression analysis and molecular biomarker research to measure pain intensity in FM patients.

Methodology:

An observational cohort study was carried out with 122 participants, divided into two groups: patients with FM (n=61) and without FM (n=61). Data collection included:

  1. Facial expression recording: A convolutional neural network algorithm was used to analyze facial patterns associated with pain.
  2. Biological samples: 1mL of saliva will be collected from each participant using the salivette method and processed to extract DNA, RNA and plasma proteins. The proteins will be quantified by ELISA and the genes associated with FM will be analyzed by RT-qPCR.
  3. Clinical Questionnaires: Psychometric instruments such as the Visual Analogue Scale (VAS) and the Generalized Pain Index (GDI) were used to validate the results.
  4. Statistical analysis: The data was analyzed using Kappa and Bland-Altman correlations to assess the agreement between the AI methods and the questionnaires, with a significance level of p\<0.05.

The AI algorithm will use consistent facial patterns correlating them to the reported pain intensity, in agreement (Kappa=0.82) with the results of the clinical scales.The molecular markers analyzed are expected to show significant differences between the groups, with increased expression of inflammatory proteins in FM patients (p\<0.05). The integration of facial and molecular analysis aims to amplify the accuracy of pain intensity classification.

This approach represents a promising advance in the diagnosis and management of the syndrome, contributing to personalized therapies and improving patients' quality of life.

03

Conditions studied

  • Fibromyalgia (FM)
  • Pain
  • Catastrophizing Pain

Keywords

  • Fibromyalgia
  • Artificial intelligence
  • Molecular biomarkers
  • Catastrophism
  • Facial expression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study will be carried out with adult patients aged between 18 and 65 diagnosed with fibromyalgia at the outpatient clinic of the Faculdade Ciências Médicas de Minas Gerais and Clínica Ampla de Reumatologia in Belo Horizonte. The inclusion criteria were patients with no diagnosed cognitive deficit and who were willing to take part in the study. The exclusion criteria are patients who use medication that can affect anxiety or depression or who are unable to understand the instructions. Thus, once the patients agree to participate, they will be asked to sign the Informed Consent Form (ICF), which will provide detailed information about the nature of the study, the criteria for participation, the possible risks and benefits involved.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The inclusion criteria are patients with no diagnosed cognitive deficit and who are willing to take part in the study.

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria are patients who use medication that can affect anxiety or depression or inability to understand the instructions.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
122 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients diagnosed with fibromyalgia

    The aim is to follow fibromyalgia patients over a period of months to analyze pain intensity and identify molecular markers associated with the condition. The study encompasses facial analysis techniques and molecular markers, along with artificial intelligence tools, to quantify pain and understand the underlying mechanisms of fibromyalgia. The methodology is predominantly quantitative, focused on collecting and analyzing objective data on pain and associated markers.

  • Patients without a diagnosis of fibromyalgia

    The aim is to follow patients with pain over a period of months to analyze the intensity and identify molecular markers associated with the condition. The study encompasses facial analysis techniques and molecular markers, along with artificial intelligence tools, to quantify pain and understand the underlying mechanisms of fibromyalgia. The methodology is predominantly quantitative, focused on collecting and analyzing objective data on pain and associated markers.

06

What researchers measure

Primary outcomes

  1. Use the artificial intelligence tool to analyze the facial expression of patients with fibromyalgia in order to recognize pain.

    Use the artificial intelligence tool to analyze the facial expression of patients with fibromyalgia in order to recognize pain. 61 patients with fibromyalgia will be compared with 61 patients without fibromyalgia.

    Time frame: The estimated time for the anamnesis is one hour, during which time biological samples will be taken and each patient's facial expressions will be recorded on camera.

Secondary outcomes

  1. Biochemical analysis of biomarkers in the detection of pain in fibromyalgia.

    122 samples containing 1ml of saliva will be collected in order to check for changes in oxidative stress and nociceptive markers (by spectrophotometry and ELISA).

    Time frame: Estimated collection and analysis time: 5 hours of durability

07

Study locations

1 of 1 sites recruiting
  • Outpatient Faculty Medical Sciences
    Belo Horizonte, Minas Gerais 30130110, Brazil
    Recruiting
08

References and documents

Publications

  • Barua VB, Juel MAI, Blackwood AD, Clerkin T, Ciesielski M, Sorinolu AJ, Holcomb DA, Young I, Kimble G, Sypolt S, Engel LS, Noble RT, Munir M. Tracking the temporal variation of COVID-19 surges through wastewater-based epidemiology during the peak of the pandemic: A six-month long study in Charlotte, North Carolina. Sci Total Environ. 2022 Mar 25;814:152503. doi: 10.1016/j.scitotenv.2021.152503. Epub 2021 Dec 23. PubMed 34954186 ↗
  • Agarwal A, Emary PC, Gallo L, Oparin Y, Shin SH, Fitzcharles MA, Adachi JD, Cooper MD, Craigie S, Rai A, Wang L, Couban RJ, Busse JW. Physicians' knowledge, attitudes, and practices regarding fibromyalgia: A systematic review and meta-analysis of cross-sectional studies. Medicine (Baltimore). 2024 Aug 2;103(31):e39109. doi: 10.1097/MD.0000000000039109. PubMed 39093781 ↗
  • Ahmad M, Ahmed I, Jeon G. A sustainable advanced artificial intelligence-based framework for analysis of COVID-19 spread. Environ Dev Sustain. 2022 Aug 16:1-16. doi: 10.1007/s10668-022-02584-0. Online ahead of print. PubMed 35993085 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Feb 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Feb 6, 2025
StartActual
Nov 17, 2025
Primary completionEst.
Feb 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06813352
Lead sponsor
Faculdade de Ciências Médicas de Minas Gerais
Collaborators
Fundação de Amparo à Pesquisa do estado de Minas Gerais, Conselho Nacional de Desenvolvimento Científico e Tecnológico
Responsible party
Alessandra Hubner de Souza (Main supervisor of the study, statistical analyst and specialist in pain studies; pHd IN Pharmacological Sciences, Faculdade de Ciências Médicas de Minas Gerais) — Principal investigator
First posted
Feb 6, 2025
Start date
Nov 17, 2025
Primary completion
Feb 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Nov 19, 2025

Study contacts

Alessandra H De Souza, PhD
Contact
alessandra.souza@cienciasmedicasmg.edu.br
55-31984205240

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion